AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 3493903 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate dose MTX (regimen II)
Number of subjects: 106
Study 3493903 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy (both regimens)
Number of subjects: 106
Study 29329979 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress induction using the socially evaluated cold‐pressor test (SECPT)
Number of subjects: 53
Study 29329979 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 53
Study 27733165 — intervention group
Group type: EXPERIMENTAL
Intervention: ibuprofen 400 mg PO and metoclopramide 10 mg PO
Number of subjects: 576
Study 27733165 — intervention group
Group type: EXPERIMENTAL
Intervention: tramadol 50 mg PO
Number of subjects: 576
Study 27733165 — intervention group
Group type: COMPARATOR
Intervention: placebo (two placebo pills)
Number of subjects: 576
Study 23558663 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiographic assessment of femoral implant position
Number of subjects: 40
Study 23579897 — intervention group
Group type: EXPERIMENTAL
Intervention: Electric torque-control motor
Number of subjects: 26
Study 23579897 — intervention group
Group type: COMPARATOR
Intervention: Air-driven handpiece
Number of subjects: 26
Study 20546277 — intervention group
Group type: EXPERIMENTAL
Intervention: Culturally appropriate health education
Number of subjects: 0
Study 20546277 — intervention group
Group type: COMPARATOR
Intervention: Usual health education
Number of subjects: 0
Study 18936219 — intervention group
Group type: EXPERIMENTAL
Intervention: C+P (carbohydrate and protein hydrolysate)
Number of subjects: 20
Study 18936219 — intervention group
Group type: COMPARATOR
Intervention: W (water only)
Number of subjects: 20
Study 16729918 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavioural therapy (CBT) in addition to mebeverine hydrochloride
Number of subjects: 149
Study 16729918 — intervention group
Group type: COMPARATOR
Intervention: mebeverine hydrochloride alone
Number of subjects: 149
Study 14671984 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-week interval between INR determinations (group 1)
Number of subjects: 124
Study 14671984 — intervention group
Group type: COMPARATOR
Intervention: 4-week interval between INR determinations (group 2, control)
Number of subjects: 124
Study 10992533 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone aqueous spray 200 microgram once daily (first season)
Number of subjects: 97
Study 10992533 — intervention group
Group type: COMPARATOR
Intervention: Placebo (first season)
Number of subjects: 97
Study 10992533 — intervention group
Group type: EXPERIMENTAL
Intervention: Beclomethasone 200 microgram twice daily (second season)
Number of subjects: 97
Study 10992533 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone (second season)
Number of subjects: 97
Study 10992533 — intervention group
Group type: COMPARATOR
Intervention: Placebo (second season)
Number of subjects: 97
Study 8792038 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral magnesium 600 mg (24 mmol) daily for 12 weeks
Number of subjects: 81
Study 8792038 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 81
Study 1377035 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose aprotinin (GpI)
Number of subjects: 90
Study 1377035 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous fresh whole blood transfusion (GpII)
Number of subjects: 90
Study 1377035 — intervention group
Group type: COMPARATOR
Intervention: Control group (GpIII)
Number of subjects: 90
Study 29248399 — intervention group
Group type: EXPERIMENTAL
Intervention: Palliative chemoradiotherapy
Number of subjects: 220
Study 29248399 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy alone
Number of subjects: 220
Study 27472271 — intervention group
Group type: EXPERIMENTAL
Intervention: Complementary and alternative medicine (CAM)
Number of subjects: 0
Study 27472271 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-IBD patients)
Number of subjects: 0
Study 27472271 — intervention group
Group type: EXPERIMENTAL
Intervention: Massage
Number of subjects: 0
Study 27472271 — intervention group
Group type: EXPERIMENTAL
Intervention: Natural products
Number of subjects: 0
Study 23399046 — intervention group
Group type: EXPERIMENTAL
Intervention: Insertion torque ≤20 Ncm
Number of subjects: 21
Study 23399046 — intervention group
Group type: COMPARATOR
Intervention: Insertion torque >50 Ncm
Number of subjects: 21
Study 23399046 — intervention group
Group type: EXPERIMENTAL
Intervention: Machined implant neck design
Number of subjects: 21
Study 23399046 — intervention group
Group type: COMPARATOR
Intervention: Anodized implant neck design
Number of subjects: 21
Study 22827973 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyphenon E (Poly E) 400 mg twice daily
Number of subjects: 40
Study 22827973 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyphenon E (Poly E) 600 mg twice daily
Number of subjects: 40
Study 22827973 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyphenon E (Poly E) 800 mg twice daily
Number of subjects: 40
Study 22827973 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 20845296 — intervention group
Group type: EXPERIMENTAL
Intervention: L‐carnitine 25 mg/day
Number of subjects: 52
Study 20845296 — intervention group
Group type: EXPERIMENTAL
Intervention: Clomiphene citrate 2 gr/day
Number of subjects: 52
Study 18665162 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary intake of thiamin, riboflavin, niacin, folate, methionine, and alcohol
Number of subjects: 4260
Study 18665162 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol consumption
Number of subjects: 4260
Study 16200756 — intervention group
Group type: EXPERIMENTAL
Intervention: EMG-triggered robot-assisted therapy
Number of subjects: 0
Study 14571302 — intervention group
Group type: EXPERIMENTAL
Intervention: Ezetimibe (cholesterol absorption inhibitor)
Number of subjects: 0
Study 14571302 — intervention group
Group type: EXPERIMENTAL
Intervention: Ezetimibe in combination with atorvastatin or simvastatin
Number of subjects: 0
Study 14571302 — intervention group
Group type: COMPARATOR
Intervention: Ezetimibe
Number of subjects: 0
Study 10770363 — intervention group
Group type: EXPERIMENTAL
Intervention: Nandrolone decanoate (50 mg, 5 injections over 3 months)
Number of subjects: 40
Study 10770363 — intervention group
Group type: COMPARATOR
Intervention: Placebo (5 injections over 3 months)
Number of subjects: 40
Study 8901790 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet containing 300 g shrimp/d (590 mg dietary cholesterol/d)
Number of subjects: 0
Study 8901790 — intervention group
Group type: COMPARATOR
Intervention: Diet containing two large eggs per day (581 mg dietary cholesterol/d)
Number of subjects: 0
Study 1829300 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine (2 x 150 mg)
Number of subjects: 0
Study 1829300 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucralfate (4 x 1 g)
Number of subjects: 0
Study 1829300 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin (2 x 50 mg for 3 weeks)
Number of subjects: 0
Study 1829300 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 6824555 — intervention group
Group type: EXPERIMENTAL
Intervention: Mianserin (Bolvidon‐Organon)
Number of subjects: 60
Study 6824555 — intervention group
Group type: COMPARATOR
Intervention: Doxepin (Sinequan‐Pfizer)
Number of subjects: 60
Study 30739941 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcostal TAP block with 10 mL of 0.25% bupivacaine
Number of subjects: 60
Study 30739941 — intervention group
Group type: COMPARATOR
Intervention: Port site infiltration with local anesthetic
Number of subjects: 60
Study 30739941 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcostal TAP block
Number of subjects: 60
Study 30369310 — intervention group
Group type: EXPERIMENTAL
Intervention: Levosimendan (loading dose 12 μg/kg + 0.1 μg/kg per minute)
Number of subjects: 32
Study 30369310 — intervention group
Group type: COMPARATOR
Intervention: Dobutamine (7.5 μg/kg per minute)
Number of subjects: 32
Study 25362579 — intervention group
Group type: EXPERIMENTAL
Intervention: Resolute zotarolimus‐eluting stent (R‐ZES)
Number of subjects: 20
Study 25280761 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress MBF and MFR measurements using (99m)Tc-sestamibi dynamic SPECT imaging
Number of subjects: 28
Study 25280761 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-operator variability measurements by expert and novice operators
Number of subjects: 28
Study 25280761 — intervention group
Group type: EXPERIMENTAL
Intervention: Inter-operator variability measurements
Number of subjects: 28
Study 21228025 — intervention group
Group type: EXPERIMENTAL
Intervention: subcutaneous interferon beta-1a (44 mcg three times weekly)
Number of subjects: 165
Study 21228025 — intervention group
Group type: EXPERIMENTAL
Intervention: intramuscular interferon beta-1a (30 mcg weekly)
Number of subjects: 165
Study 21228025 — intervention group
Group type: EXPERIMENTAL
Intervention: glatiramer acetate (20 mg daily)
Number of subjects: 165
Study 21228025 — intervention group
Group type: COMPARATOR
Intervention: untreated patients (reference population)
Number of subjects: 165
Study 20819471 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicillin/clavulanate for 2 weeks after ESS
Number of subjects: 75
Study 20819471 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study 16428941 — intervention group
Group type: EXPERIMENTAL
Intervention: Metopimazine (7.5 mg x 2 t.i.d.)
Number of subjects: 200
Study 16428941 — intervention group
Group type: COMPARATOR
Intervention: Ondansetron (8 mg b.i.d.)
Number of subjects: 200
Study 12937336 — intervention group
Group type: EXPERIMENTAL
Intervention: Coping With Caregiving psychoeducational program
Number of subjects: 213
Study 12937336 — intervention group
Group type: COMPARATOR
Intervention: Enhanced Support Group condition
Number of subjects: 213
Study 11079649 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate availability of myoglobin/CK-MB results at 0 and 1 hour after enrollment (stat)
Number of subjects: 6352
Study 11079649 — intervention group
Group type: COMPARATOR
Intervention: Conventional reporting of myoglobin/CK-MB 3 hours or more after hospital admission (control)
Number of subjects: 6352
Study 11079649 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate availability of myoglobin/CK-MB results (stat)
Number of subjects: 6352
Study 11079649 — intervention group
Group type: COMPARATOR
Intervention: Conventional reporting of myoglobin/CK-MB (control)
Number of subjects: 6352
Study 9051024 — intervention group
Group type: EXPERIMENTAL
Intervention: Portal venous flow measurement by sonographers
Number of subjects: 5
Study 1585407 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasted condition
Number of subjects: 17
Study 1585407 — intervention group
Group type: EXPERIMENTAL
Intervention: Fed condition
Number of subjects: 17
Study 1585407 — intervention group
Group type: COMPARATOR
Intervention: Comparison of fasted and fed conditions
Number of subjects: 17
Study 2865674 — intervention group
Group type: EXPERIMENTAL
Intervention: Bypass surgery joining the superficial temporal artery and the middle cerebral artery
Number of subjects: 1377
Study 2865674 — intervention group
Group type: COMPARATOR
Intervention: Best medical care
Number of subjects: 1377
Study 31631248 — intervention group
Group type: EXPERIMENTAL
Intervention: Letrozole step-up protocol (Group A)
Number of subjects: 60
Study 31631248 — intervention group
Group type: COMPARATOR
Intervention: Letrozole plus hMG (Group B)
Number of subjects: 60
Study 29026170 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose AN-PEP
Number of subjects: 18
Study 29026170 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose AN-PEP
Number of subjects: 18
Study 29026170 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 26530933 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-carbohydrate and low-GI diets
Number of subjects: 91
Study 26530933 — intervention group
Group type: COMPARATOR
Intervention: High-carbohydrate and high-GI diets
Number of subjects: 91
Study 26530933 — intervention group
Group type: EXPERIMENTAL
Intervention: Diets varying in carbohydrate and glycemic index
Number of subjects: 91
Study 23891460 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone brief intervention (n=68)
Number of subjects: 131
Study 23891460 — intervention group
Group type: COMPARATOR
Intervention: In-person brief intervention (n=63)
Number of subjects: 131
Study 21898717 — intervention group
Group type: EXPERIMENTAL
Intervention: Augmentation with buspirone
Number of subjects: 269
Study 21898717 — intervention group
Group type: EXPERIMENTAL
Intervention: Switching to venlafaxine
Number of subjects: 269
Study 21898717 — intervention group
Group type: EXPERIMENTAL
Intervention: Switching to bupropion
Number of subjects: 269
Study 21898717 — intervention group
Group type: COMPARATOR
Intervention: Augmentation strategy
Number of subjects: 269
Study 21898717 — intervention group
Group type: COMPARATOR
Intervention: Switch strategy
Number of subjects: 269
Study 19865631 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical-grade calcium sulfate hemihydrate (MGCSH)
Number of subjects: 40
Study 19865631 — intervention group
Group type: COMPARATOR
Intervention: No grafting material (control)
Number of subjects: 40
Study 16923370 — intervention group
Group type: EXPERIMENTAL
Intervention: Child and parent safety education programs
Number of subjects: 0
Study 16923370 — intervention group
Group type: COMPARATOR
Intervention: Control group (no injury prevention education)
Number of subjects: 0
Study 15212845 — intervention group
Group type: EXPERIMENTAL
Intervention: Hippocampal volume (HcV)
Number of subjects: 105
Study 15212845 — intervention group
Group type: EXPERIMENTAL
Intervention: Normalised HcV and intracranial volume (ICV)
Number of subjects: 105
Study 15212845 — intervention group
Group type: EXPERIMENTAL
Intervention: Normalised brain volume (BV) and ICV
Number of subjects: 105
Study 15212845 — intervention group
Group type: EXPERIMENTAL
Intervention: Absolute volumetric measures of HcV and BV
Number of subjects: 105
Study 15212845 — intervention group
Group type: EXPERIMENTAL
Intervention: Widespread brain atrophy
Number of subjects: 105
Study 11777630 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored chemotherapy (FEC: cyclophosphamide, epirubicin, 5‐fluorouracil)
Number of subjects: 34
Study 11777630 — intervention group
Group type: COMPARATOR
Intervention: Standard chemotherapy (CTCb: cyclophosphamide, thiotepa, carboplatin)
Number of subjects: 34
Study 10728155 — intervention group
Group type: EXPERIMENTAL
Intervention: Body weight treatment
Number of subjects: 11
Study 10728155 — intervention group
Group type: COMPARATOR
Intervention: Body fat treatment (measured by anthropometrics)
Number of subjects: 11
Study 8083704 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly chemotherapy (12 alternating cycles of ifosfamide/doxorubicin and cis-platin/etoposide)
Number of subjects: 438
Study 8083704 — intervention group
Group type: COMPARATOR
Intervention: 3-week chemotherapy (6 alternating cycles of cyclophosphamide/doxorubicin/vincristine and PE)
Number of subjects: 438
Study 8083704 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly chemotherapy
Number of subjects: 438
Study 8083704 — intervention group
Group type: COMPARATOR
Intervention: 3-week chemotherapy
Number of subjects: 438
Study 2670465 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin (IV 200 to 300 mg twice daily, followed by oral 500 mg twice daily)
Number of subjects: 122
Study 2670465 — intervention group
Group type: COMPARATOR
Intervention: Ceftazidime (IV 1 to 2 g two to three times daily)
Number of subjects: 122
Study 2670465 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin
Number of subjects: 122
Study 59850 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromocriptine (mean daily dose 79 mg)
Number of subjects: 20
Study 31241736 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical doctors performing inguinal hernia repair with mesh
Number of subjects: 242
Study 31241736 — intervention group
Group type: COMPARATOR
Intervention: Surgeons performing inguinal hernia repair with mesh
Number of subjects: 242
Study 31241736 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical doctors
Number of subjects: 242
Study 31241736 — intervention group
Group type: COMPARATOR
Intervention: Surgeons
Number of subjects: 242
Study 29132482 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional Electrical Stimulation (FES)
Number of subjects: 0
Study 29132482 — intervention group
Group type: COMPARATOR
Intervention: Electrical Muscle Stimulation (EMS)
Number of subjects: 0
Study 25528557 — intervention group
Group type: EXPERIMENTAL
Intervention: Portrayals of untreated schizophrenia, depression, and heroin addiction
Number of subjects: 3940
Study 25528557 — intervention group
Group type: EXPERIMENTAL
Intervention: Portrayals of successfully treated schizophrenia, prescription painkiller addiction, and heroin addiction
Number of subjects: 3940
Study 25528557 — intervention group
Group type: COMPARATOR
Intervention: Control vignette
Number of subjects: 3940
Study 22749926 — intervention group
Group type: EXPERIMENTAL
Intervention: Chewing tobacco containing nicotine for 1 hour after TDT training
Number of subjects: 0
Study 22749926 — intervention group
Group type: COMPARATOR
Intervention: Control substance without nicotine
Number of subjects: 0
Study 21477846 — intervention group
Group type: EXPERIMENTAL
Intervention: Tinzaparin 175 IU/kg once daily
Number of subjects: 539
Study 21477846 — intervention group
Group type: COMPARATOR
Intervention: Activated partial thromboplastin time‐adjusted UFH twice daily
Number of subjects: 539
Study 21477846 — intervention group
Group type: EXPERIMENTAL
Intervention: Tinzaparin
Number of subjects: 539
Study 21477846 — intervention group
Group type: COMPARATOR
Intervention: UFH
Number of subjects: 539
Study 18651985 — intervention group
Group type: EXPERIMENTAL
Intervention: Tele-based nurse delivered five session decision support/psychosocial intervention
Number of subjects: 700
Study 18651985 — intervention group
Group type: COMPARATOR
Intervention: Usual care control group
Number of subjects: 700
Study 17029522 — intervention group
Group type: EXPERIMENTAL
Intervention: Tribochemical silica coating combined with silane
Number of subjects: 20
Study 17029522 — intervention group
Group type: COMPARATOR
Intervention: No treatment (Control)
Number of subjects: 20
Study 15241100 — intervention group
Group type: EXPERIMENTAL
Intervention: Bird 8400 STi ventilator at 5 breaths/min
Number of subjects: 8
Study 15241100 — intervention group
Group type: EXPERIMENTAL
Intervention: Bird 8400 STi ventilator at 10 breaths/min
Number of subjects: 8
Study 15241100 — intervention group
Group type: COMPARATOR
Intervention: Servo‐300 ventilator at 5 breaths/min
Number of subjects: 8
Study 15241100 — intervention group
Group type: COMPARATOR
Intervention: Servo‐300 ventilator at 10 breaths/min
Number of subjects: 8
Study 11531035 — intervention group
Group type: EXPERIMENTAL
Intervention: Emergency oxygen device 1
Number of subjects: 9
Study 11531035 — intervention group
Group type: EXPERIMENTAL
Intervention: Emergency oxygen device 2
Number of subjects: 9
Study 11531035 — intervention group
Group type: EXPERIMENTAL
Intervention: Emergency oxygen device 3
Number of subjects: 9
Study 11531035 — intervention group
Group type: EXPERIMENTAL
Intervention: Emergency oxygen device 4
Number of subjects: 9
Study 9160033 — intervention group
Group type: EXPERIMENTAL
Intervention: lodoxamide tromethamine 0.1%
Number of subjects: 20
Study 9160033 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 20
Study 7956336 — intervention group
Group type: EXPERIMENTAL
Intervention: Tretinoin cream (0.025 percent) applied daily for seven months
Number of subjects: 11
Study 7956336 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 11
Study 3262546 — intervention group
Group type: EXPERIMENTAL
Intervention: miocamycin 50 mg/kg.day
Number of subjects: 23
Study 3262546 — intervention group
Group type: COMPARATOR
Intervention: amoxycillin 60 mg/kg.day
Number of subjects: 23
Study 31125988 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg nicotine gum
Number of subjects: 369
Study 31125988 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 369
Study 31317669 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium phosphate (CaP)‐coated SLA surface implants
Number of subjects: 34
Study 31317669 — intervention group
Group type: COMPARATOR
Intervention: Conventional SLA surface implants
Number of subjects: 34
Study 27690294 — intervention group
Group type: EXPERIMENTAL
Intervention: CIK cell immunotherapy combined with standard TMZ chemoradiotherapy
Number of subjects: 180
Study 27690294 — intervention group
Group type: COMPARATOR
Intervention: Standard TMZ chemoradiotherapy alone (control group)
Number of subjects: 180
Study 24645829 — intervention group
Group type: EXPERIMENTAL
Intervention: Smart phone-based app (EPI app) used by village doctors
Number of subjects: 36
Study 24645829 — intervention group
Group type: COMPARATOR
Intervention: Usual immunization management by village doctors (Control)
Number of subjects: 36
Study 22834649 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal 1% testosterone gel (5-7.5 mg/day)
Number of subjects: 362
Study 22834649 — intervention group
Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 362
Study 20485136 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery
Number of subjects: 838
Study 20485136 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 838
Study 18046027 — intervention group
Group type: EXPERIMENTAL
Intervention: Eltrombopag 30 mg
Number of subjects: 74
Study 18046027 — intervention group
Group type: EXPERIMENTAL
Intervention: Eltrombopag 50 mg
Number of subjects: 74
Study 18046027 — intervention group
Group type: EXPERIMENTAL
Intervention: Eltrombopag 75 mg
Number of subjects: 74
Study 18046027 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 74
Study 16042648 — intervention group
Group type: EXPERIMENTAL
Intervention: High resistance group (standardized patient portraying high resistance)
Number of subjects: 32
Study 16042648 — intervention group
Group type: COMPARATOR
Intervention: Low resistance group (standardized patient portraying low resistance)
Number of subjects: 32
Study 12405489 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled fluticasone
Number of subjects: 22
Study 12405489 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 10443608 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg/kg rectal acetaminophen
Number of subjects: 120
Study 10443608 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg/kg rectal acetaminophen
Number of subjects: 120
Study 10443608 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120